- Full text PDF available (1)
- This year (0)
- Last 5 years (1)
- Last 10 years (9)
Journals and Conferences
The intent of the voluntary Competitive Acquisition Program is to relieve physicians of the substantive up-front costs needed to buy Part B drugs and biologics. Will it work?
The cost of biologic therapies adds urgency to the need to develop realistic compliance strategies. By engaging and educating both the physician and patient, some MCOs are working hard to address at what has always been a complicated and formidable issue.
Biotech's course through 2005 will hinge on five key variables: Use of electronic medical records to speed data collectionClarifying sources of investment capitalKeeping clinicians currentReshaping benefit designs to cope with new and costly productsAnd, above all, defining and proving the value of biotech products Here's a look at how these issues could… (More)